Document is current
Any future updates will be listed below
-
Authors
Kim, Sonia B. https://orcid.org/0009-0002-4827-6906
Zhou, Melody
Kaelber, David C.
Talcott, Katherine E.
Singh, Rishi P. https://orcid.org/0000-0001-5859-8162
-
Funding
Funding for this research was provided by:
Case Western Reserve University School of Medicine | Clinical and Translational Science Collaborative of Cleveland, School of Medicine, Case Western Reserve University (UL1TR002548)
Research to Prevent Blindness (P30EY025585(BA-A))
- License Information
-
More Information
Article History
Received: 31 July 2025
Revised: 6 March 2026
Accepted: 23 April 2026
First Online: 4 May 2026
Competing interests
: DK reports grants from National Institutes of Health (Washington, DC) and Patient-Centred Outcomes Research Institute (PCORI) (Washington, DC); and has volunteer leadership at Epic Corporation (Verona, WI) and TriNetX Corporation (Boston, MA). RS reports personal fees from Apellis, Iveric Bio/Astellas, Eyepoint, Regenxbio, Genentech, Bausch and Lomb, Zeiss, Alcon, Regeneron, Outlook, and Aviceda; research fees from Janssen; and equity in Sanro, Aviceda, and Olin. KT reports consulting fees from 4DMT, Alimera, Abbvie, Apellis, Astellas, Bausch and Lomb, Eyepoint, Genentech, Harrow, Ocular Therapeutics, Outlook, Regeneron, and Zeiss; research fees from Regeneron and Zeiss; and speaking fees from Astellas, Genentech, and Zeiss.
